Dr. Sung Choi on Vorinostat in GVHD Prevention
December 14th 2012Sung W. Choi, MD, Assistant Professor, University of Michigan, discusses the results of a phase I/II trial examining the use of the histone deacetylase (HDAC) inhibitor vorinostat in graft-versus-host disease (GVHD) prevention.
Read More
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Both Gastric and Breast HER2 Scoring Algorithms Applicable in mCRC Testing
Encorafenib Plus Cetuximab and Chemotherapy Demonstrates Safety, Efficacy in BRAF V600E–Mutant mCRC